(CME Satellite Symposia) From Inflammation to Individualization: Advances in Precision Medicine and Novel Anti-TL1A Therapies for Inflammatory Bowel Disease

Supported by educational grants from Genentech, a member of the Roche Group and Merck & Co., Inc., Rahway, NJ, USA. Despite major advances, IBD management remains challenging due to disease heterogeneity and diagnostic complexity. Clinicians often struggle to tailor treatment strategies and differentiate goals for Crohn’s disease versus ulcerative colitis. Precision medicine offers a pathway to individualized care through comprehensive assessment, imaging, and targeted therapies. This session will explore emerging tools, assays, and biologics that can help gastroenterology teams optimize treatment decisions and improve outcomes. Learning Objectives - Apply innovative technologies and precision medicine tools to accurately identify/characterize IBD, including CD and UC, and guide individualized therapeutic decisions - Examine the impact of IBD disease heterogeneity, including chronic inflammation and complications such as strictures, on disease management and progression - Evaluate the clinical data, therapeutic potential, and mechanisms of action of novel anti-TL1A monoclonal antibodies for the treatment of IBD - Address the complexities of IBD through personalized management strategies that consider evidence-based risk stratification, biomarker utilization, TDM, and interdisciplinary care